Download PDF
Semin Vasc Med 2003; 03(2): 123-130
DOI: 10.1055/s-2003-40670
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

GPIIb/IIIa Antagonists and Other Anti-Integrins

Alan T. Nurden, Paquita Nurden
  • Laboratoire d'Hematologie, UMR 5533 CNRS, Hôpital Cardiologique, Pessac, France
Further Information

Publication History

Publication Date:
18 July 2003 (online)

    Permissions and Reprints

ABSTRACT

Platelet aggregation involves the binding of adhesive proteins (fibrinogen, von Willebrand factor) to the αIIbβ3 integrin, which assumes a high-affinity state for adhesive proteins during platelet activation. The occupied integrin sends signals back into the platelet, and the bound adhesive protein forms the bridges linking platelets together. Anti-integrin therapy is designed to inhibit this process in arterial thrombosis. Abciximab, mouse-human chimeric Fab fragments, blocks platelet aggregation and provides proven clinical benefit in acute situations such as in patients with unstable angina undergoing angioplasty or stenting. Eptifibatide and tirofiban are small molecular mass inhibitors also in current use. In contrast, oral inhibitors of αIIbβ3 have proved disappointing, provoking increased mortality without assuring an adequate blockade of αIIbβ3. The problems of using anti-integrin therapy are discussed in this article as are ways of improving its efficacity. Final thoughts provide ideas for a new generation of inhibitors.

KEYWORDS

Anti-integrin therapy - αIIbβ3 - platelets - arterial thrombosis

REFERENCES

  • 1 Italiano J E, Lecine P, Shivdasani R A, Hartwig J H. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes.  J Cell Biol . 1999;  147 1299-1312
    CrossrefPubMedGoogle Scholar
  • 2 Savage B, Almus-Jacobs F, Ruggeri Z M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow.  Cell . 1998;  94 657-666
    CrossrefPubMedGoogle Scholar
  • 3 Nurden A T, George J N. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis, Basic Principles and Clinical Practice Philadelphia, PA: Lippincott, Williams & Wilkins 2000: 921-943
    Google Scholar
  • 4 Plow E F, Cierniewski C S, Xiao Z. αIIbβ3 and its antagonism in the new millenium.  Thromb Haemost . 2001;  96 34-40
    PubMedGoogle Scholar
  • 5 Shattil S J, Kashiwagi H, Pampori N. Integrin signalling: the platelet paradigm.  Blood . 1998;  91 2645-2657
    PubMedGoogle Scholar
  • 6 Woodside D G, Liu S, Ginsberg M H. Integrin activation.  Thromb Haemost . 2001;  86 316-323
    PubMedGoogle Scholar
  • 7 Phillips D R, Nannizzi-Alaimo L, Prasad K SS. β3 tyrosine phosphorylation in αIIbβ3 (platelet membrane GP IIb-IIIa) outside-in integrin signaling.  Thromb Haemost . 2001;  86 246-258
    PubMedGoogle Scholar
  • 8 Gawaz M P, Loftus J C, Bajt M L. Ligand bridging mediates integrin αIIbβ3 (platelet GPIIbIIIa) dependent homotypic and heterotypic interactions.  J Clin Invest . 1991;  88 1128-1134
    CrossrefPubMedGoogle Scholar
  • 9 Coller B S. Anti-GPIIb/IIIa drugs: current strategies and future directions.  Thromb Haemost . 2001;  86 427-443
    PubMedGoogle Scholar
  • 10 Bhatt D L, Topol E J. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.  JAMA . 2000;  284 1549-1558
    CrossrefPubMedGoogle Scholar
  • 11 Puzon-McLaughlin W, Kamata T, Takada Y. Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding pocket in integrin αIIbβ3.  J Biol Chem . 2000;  275 7795-7802
    CrossrefPubMedGoogle Scholar
  • 12 Mascelli M A, Lance E T, Damaraju L. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb-IIIa receptor blockade.  Circulation . 1998;  97 1680-1688
    PubMedGoogle Scholar
  • 13 Nurden P, Poujol C, Durrieu-Jais C. Labeling of the internal pool of GPIIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport.  Blood . 1999;  93 1622-1633
    PubMedGoogle Scholar
  • 14 Kleiman N S, Raizner A E, Jordan R. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb-IIIa receptors.  J Am Coll Cardiol . 1995;  26 1665-1671
    CrossrefPubMedGoogle Scholar
  • 15 Bihour C, Durrieu-Jais C, Macchi L. Expression of markers of platelet activation and the interpatient variation in response to abciximab.  Arterioscler Thromb Vasc Biol . 1999;  19 212-219
    PubMedGoogle Scholar
  • 16 Phillips D R, Teng W, Arsften A. Effect of Ca2+ on GPIIb-IIIa interactions with integrilin. Enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.  Circulation . 1997;  96 1488-1494
    CrossrefPubMedGoogle Scholar
  • 17 The IMPACT investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II.  Lancet . 1997;  349 1422-1428
    CrossrefPubMedGoogle Scholar
  • 18 The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.  Circulation . 1997;  96 1445-1453
    PubMedGoogle Scholar
  • 19 O'Neill W W, Serruys P, Knudtson M. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization.  N Engl J Med . 2000;  342 1316-1324
    CrossrefPubMedGoogle Scholar
  • 20 Quinn M J, Cox D J, Foley J B. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.  J Pharmacol Exp Ther . 2000;  295 670-676
    PubMedGoogle Scholar
  • 21 Cannon C P, McCabe C H, Wilcox R G. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.  Circulation . 2000;  102 149-156
    PubMedGoogle Scholar
  • 22 Cox D, Smith R, Quinn M. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients with acute coronary syndromes.  J Am Coll Cardiol . 2000;  36 1514-1519
    CrossrefPubMedGoogle Scholar
  • 23 Alderley S, Fitzgerald D. Glycoprotein IIb-IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation.  J Biol Chem . 2000;  275 5760-5766
    CrossrefPubMedGoogle Scholar
  • 24 Reverter J C, Beguin S, Kessels H. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and `clinical restenosis'.  J Clin Invest . 1996;  98 863-874
    CrossrefPubMedGoogle Scholar
  • 25 Peter K, Schwartz M, Ylänne J. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors.  Blood . 1998;  92 3240-3249
    PubMedGoogle Scholar
  • 26 Ndoko S, Poujol C, Combrié R. Paradoxical platelet activation was not observed after dissociation of c7E3 (abciximab) from GPIIb-IIIa complexes.  Thromb Haemost . 2002;  87 317-322
    PubMedGoogle Scholar
  • 27 Peter K, Straub A, Kohler B. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.  Am J Cardiol . 1999;  84 519-524
    CrossrefPubMedGoogle Scholar
  • 28 Ault K A, Cannon C P, Mitchell J. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial.  J Am Coll Cardiol . 1999;  33 634-639
    CrossrefPubMedGoogle Scholar
  • 29 Steinhubl S R, Kottke-Marchant K, Molierno D J. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.  Circulation . 1999;  100 1977-1982
    PubMedGoogle Scholar
  • 30 Steinhubl S R, Talley J D, Braden G A. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the Gold (AU-assessing Ultegra) Multicenter Study.  Circulation . 2001;  102 2572-2578
    PubMedGoogle Scholar
  • 31 Hollopeter G, Jantzen H M, Vincent D. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature . 2001;  409 202-207
    CrossrefPubMedGoogle Scholar
  • 32 Law D A, DeGuzman F R, Heiser P. Integrin cytoplasmic tyrosine motif is required for outside-in αIIbβ3 signalling and platelet function.  Nature . 1999;  401 808-811
    CrossrefPubMedGoogle Scholar
  • 33 Rooney M M, Parise L V, Lord S T. Dissecting clot retraction and platelet aggregation. Clot retraction does not require an intact fibrinogen gamma chain C terminus.  J Biol Chem . 1996;  271 8553-8555
    CrossrefPubMedGoogle Scholar
  • 34 Ni H, Dennis C V, Subbarao S. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.  J Clin Invest . 2000;  106 385-392
    CrossrefPubMedGoogle Scholar
  • 35 André P, Denis C V, Papalia J M, Wagner D D. Defect in arterial thrombus formation in CD40L -/- mice. Thromb Haemost. CD-ROM Suppl July 2001; abstr OC1704
    Google Scholar
  • 36 Kupatt C, Habazettl H, Hanusch P. C7E3Fab re- duces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury.  Arterioscler Thromb Vasc Biol . 2000;  20 2226-2232
    PubMedGoogle Scholar
  • 37 Curley G P, Blum H, Humphries M J. Integrin antagonists.  Cell Mol Life Sci . 1999;  56 427-441
    CrossrefPubMedGoogle Scholar